SAINTE-FOY, QUEBEC--(Marketwire - April 10, 2008) - Bioxel Pharma Inc.(TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced that, on March 27, 2008, its Board of Directors granted 365,000 common share purchase options to its officers and employees, pursuant to its stock option plan. These options were granted at an exercise price of $0.135 per share, being the closing price of the Corporation’s common shares on the TSX Venture Exchange on the last business day preceding the grant date. It should be pointed out that 769,000 options expired between January 1 and April 8, 2008.
